Katarzyna Chmielewska, Joanna Janus, Jolanta Antoniewicz-Papis
Serum-based artificial tears are becoming increasingly popular worldwide. During the ISBT (International Society of Blood Transfusion) congress held in Gothenburg, Sweden, in 2023, research centers from various countries shared their experiences on the topic. Artificial tears are primarily used in the treatment of dry eye syndrome (DES), a condition associated with abnormal secretion of the tear film. Visual disturbances and headaches associated with DES have a negative impact on every day activity. In his 2021 study, Papas states that the prevalence of DES is growing and currently affects nearly 10% of the global population [1]. Because the procedure of collecting blood from older individuals or persons undergoing cancer treatment may often prove problematic, more attention
{"title":"Issues related to artificial tears were discussed at the 33rd Regional Congress of the International Society of Blood Transfusion (ISBT) in Gothenburg, June 17–21, 2023","authors":"Katarzyna Chmielewska, Joanna Janus, Jolanta Antoniewicz-Papis","doi":"10.5603/jtm.97618","DOIUrl":"https://doi.org/10.5603/jtm.97618","url":null,"abstract":"Serum-based artificial tears are becoming increasingly popular worldwide. During the ISBT (International Society of Blood Transfusion) congress held in Gothenburg, Sweden, in 2023, research centers from various countries shared their experiences on the topic. Artificial tears are primarily used in the treatment of dry eye syndrome (DES), a condition associated with abnormal secretion of the tear film. Visual disturbances and headaches associated with DES have a negative impact on every day activity. In his 2021 study, Papas states that the prevalence of DES is growing and currently affects nearly 10% of the global population [1]. Because the procedure of collecting blood from older individuals or persons undergoing cancer treatment may often prove problematic, more attention","PeriodicalId":52961,"journal":{"name":"Global Journal of Transfusion Medicine","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136277868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Katarzyna Chmielewska, Joanna Janus, Jolanta Antoniewicz-Papis
{"title":"Zagadnienia dotyczące sztucznych łez poruszone na 33. Regionalnym Kongresie International Society of Blood Transfusion (ISBT) w Goteborgu, 17–21 czerwca 2023 roku","authors":"Katarzyna Chmielewska, Joanna Janus, Jolanta Antoniewicz-Papis","doi":"10.5603/jtm.97403","DOIUrl":"https://doi.org/10.5603/jtm.97403","url":null,"abstract":"","PeriodicalId":52961,"journal":{"name":"Global Journal of Transfusion Medicine","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135040889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joanna Janus, Katarzyna Chmielewska, Jolanta Antoniewicz-Papis
The International Society of Blood Transfusion (ISBT) is a leading society combining a global community of professionals who share the knowledge on clinical and laboratory transfusion, as well as the safety of blood and blood components for the welfare of blood donors and patients. Every two years ISBT organizes international and regional congresses. On June 17–21, the 33rd Regional Congress was hosted by Göteborg (Sweden). This congress was organized jointly with the Swedish Society for Clinical Immunology and Transfusion Medicine (KITM, Svensk Förening för Klinisk Immunologi och Transfusionsmedicin). The congress agenda included: Nordic Day (June 17), during which reports from five Scandinavian countries were presented, Academy Day (June 18), during which educational lectures covering practical aspects of the most recent topics in transfusion medicine were presented, three days (June 19–21) of sessions presenting the latest reports in the field of transfusion medicine and the related fields. This paper presents some selected issues related to cell therapies presented during the Congress.
{"title":"Selected issues regarding cell therapies in light of reports presented at the 33rd Regional Congress of the International Society of Blood Transfusion (ISBT) in Gothenburg, June 17–21, 2023","authors":"Joanna Janus, Katarzyna Chmielewska, Jolanta Antoniewicz-Papis","doi":"10.5603/jtm.97617","DOIUrl":"https://doi.org/10.5603/jtm.97617","url":null,"abstract":"The International Society of Blood Transfusion (ISBT) is a leading society combining a global community of professionals who share the knowledge on clinical and laboratory transfusion, as well as the safety of blood and blood components for the welfare of blood donors and patients. Every two years ISBT organizes international and regional congresses. On June 17–21, the 33rd Regional Congress was hosted by Göteborg (Sweden). This congress was organized jointly with the Swedish Society for Clinical Immunology and Transfusion Medicine (KITM, Svensk Förening för Klinisk Immunologi och Transfusionsmedicin). The congress agenda included: Nordic Day (June 17), during which reports from five Scandinavian countries were presented, Academy Day (June 18), during which educational lectures covering practical aspects of the most recent topics in transfusion medicine were presented, three days (June 19–21) of sessions presenting the latest reports in the field of transfusion medicine and the related fields. This paper presents some selected issues related to cell therapies presented during the Congress.","PeriodicalId":52961,"journal":{"name":"Global Journal of Transfusion Medicine","volume":"2013 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136277869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the clinical presence of thrombotic episodes, and — in women — obstetric complications with the laboratory presence of antiphospholipid antibodies in blood. The main objective of this report is to present in detail the new American College of Rheumatology (ACR)/Alliance of Associations for Rheumatology (EULAR) APS classification criteria. According to EULAR methodology they include entry criterion indispensable to initiate classification process and contain 8 clinical and laboratory domains allowing to classify patient as having APS with 99% specificity.
{"title":"New classification criteria for antiphospholipid syndrome — 2023","authors":"Jacek Musiał","doi":"10.5603/jtm.97795","DOIUrl":"https://doi.org/10.5603/jtm.97795","url":null,"abstract":"Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the clinical presence of thrombotic episodes, and — in women — obstetric complications with the laboratory presence of antiphospholipid antibodies in blood. The main objective of this report is to present in detail the new American College of Rheumatology (ACR)/Alliance of Associations for Rheumatology (EULAR) APS classification criteria. According to EULAR methodology they include entry criterion indispensable to initiate classification process and contain 8 clinical and laboratory domains allowing to classify patient as having APS with 99% specificity.","PeriodicalId":52961,"journal":{"name":"Global Journal of Transfusion Medicine","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135040878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wiktoria Ryżewska, Michał Witkowski, Tadeusz Robak
Nabyta hemofilia A to skaza krwotoczna o podłożu autoimmunologicznym, której leczenie obejmuje immunosupresję i leczenie omijające inhibitor, między innymi rekombinowanym czynnikiem VIIa (rFVIIa). Czas półtrwania rFVIIa jest krótki, co wymaga częstej podaży leku w celu utrzymania hemostazy. Zapewnienie ciągłego wlewu z pompy infuzyjnej zamiast podaży bolusów może się okazać nie tylko korzystne czasowo i finansowo, ale również bardziej bezpieczne dla pacjenta ze względu na możliwość utrzymania stałego poziomu czynnika omijającego inhibitor. Zazwyczaj rFVIIa jest podawany dożylnie poprzez cewnik wprowadzany obwodowo. Ciekawą alternatywę dla pacjentów poddawanym leczeniu dożylnemu lub dla osób z trudnym dostępem naczyniowym stanowi wkłucie pośrednie (midline insertion). Założenie takiego wkłucia jest bezpieczniejsze dla pacjenta, a ryzyko infekcji można porównać z ryzykiem przy zastosowaniu innych obwodowych cewników żylnych. Zastosowanie techniki wkłucia pośredniego stanowi mniejsze zagrożenie dla pacjentów i pozwala obniżyć koszty leczenia. W niniejszym artykule przedstawiono przypadek pacjentki z nabytą hemofilią A, której podawano rFVIIa przez cewnik pośredni (midline) przy użyciu pompy infuzyjnej.
获得性血友病 A 是一种自身免疫性出血性疾病，治疗方法包括免疫抑制和抑制剂旁路疗法，包括重组因子 VIIa（rFVIIa）。rFVIIa 的半衰期很短，需要频繁输注药物以维持止血。事实证明，用输液泵持续输注而不是栓剂给药不仅能节省时间和金钱，还能维持抑制剂通过因子的恒定水平，因此对患者更安全。通常，rFVIIa 是通过外周插入导管静脉注射的。对于接受静脉注射治疗的患者或血管通路不畅的患者来说，一个有趣的替代方法是中线插入。这种方法对患者更安全，而且感染风险可与其他外周静脉导管相比。使用中线插入技术可降低患者的风险，并减少治疗费用。本文介绍了一名获得性血友病 A 患者使用输液泵通过间接（中线）导管注射 rFVIIa 的病例。
{"title":"Nabyta hemofilia A leczona rekombinowanym czynnikiem VIIa z użyciem pompy infuzyjnej i wkłucia pośredniego","authors":"Wiktoria Ryżewska, Michał Witkowski, Tadeusz Robak","doi":"10.5603/jtm.94832","DOIUrl":"https://doi.org/10.5603/jtm.94832","url":null,"abstract":"Nabyta hemofilia A to skaza krwotoczna o podłożu autoimmunologicznym, której leczenie obejmuje immunosupresję i leczenie omijające inhibitor, między innymi rekombinowanym czynnikiem VIIa (rFVIIa). Czas półtrwania rFVIIa jest krótki, co wymaga częstej podaży leku w celu utrzymania hemostazy. Zapewnienie ciągłego wlewu z pompy infuzyjnej zamiast podaży bolusów może się okazać nie tylko korzystne czasowo i finansowo, ale również bardziej bezpieczne dla pacjenta ze względu na możliwość utrzymania stałego poziomu czynnika omijającego inhibitor. Zazwyczaj rFVIIa jest podawany dożylnie poprzez cewnik wprowadzany obwodowo. Ciekawą alternatywę dla pacjentów poddawanym leczeniu dożylnemu lub dla osób z trudnym dostępem naczyniowym stanowi wkłucie pośrednie (midline insertion). Założenie takiego wkłucia jest bezpieczniejsze dla pacjenta, a ryzyko infekcji można porównać z ryzykiem przy zastosowaniu innych obwodowych cewników żylnych. Zastosowanie techniki wkłucia pośredniego stanowi mniejsze zagrożenie dla pacjentów i pozwala obniżyć koszty leczenia. W niniejszym artykule przedstawiono przypadek pacjentki z nabytą hemofilią A, której podawano rFVIIa przez cewnik pośredni (midline) przy użyciu pompy infuzyjnej.","PeriodicalId":52961,"journal":{"name":"Global Journal of Transfusion Medicine","volume":"2014 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135040890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zaburzenia funkcji płytek krwi (PFD) to rzadko występująca, a zarazem heterogenna grupa chorób należących do skaz krwotocznych. Kompleksowa diagnostyka nieprawidłowej funkcji płytek krwi (PLT), tzw. trombocytopatii — wymaga zastosowania specjalistycznych badań. Złotym standardem diagnostyki PFD jest agregometria optyczna oparta na pomiarze światła widzialnego (LTA). Do próbki badanego osocza bagatopłytkowego dodawany jest w odpowiednim stężeniu określony agonista agregacji PLT (ADP, kwas arachidonowy, kolagen, rystocetyna, epinefryna). Na skutek interakcji z agonistą dochodzi do aktywacji i następczej agregacji płytek krwi. Powstawaniu agregatów płytkowych towarzyszy proporcjonalny wzrost przepuszczalności światła. W pracy przedstawiono zasadę metody LTA wraz z omówieniem podstawowego panelu agonistów agregacji płytek krwi. Ponadto scharakteryzowano mocne strony metody LTA i ograniczenia oraz porównano ją z pozostałymi alternatywnymi metodami diagnostyki PFD.
{"title":"Testy agregometrii optycznej w diagnostyce trombocytopatii","authors":"Daria Malarczyk, Edyta Odnoczko","doi":"10.5603/jtm.95255","DOIUrl":"https://doi.org/10.5603/jtm.95255","url":null,"abstract":"Zaburzenia funkcji płytek krwi (PFD) to rzadko występująca, a zarazem heterogenna grupa chorób należących do skaz krwotocznych. Kompleksowa diagnostyka nieprawidłowej funkcji płytek krwi (PLT), tzw. trombocytopatii — wymaga zastosowania specjalistycznych badań. Złotym standardem diagnostyki PFD jest agregometria optyczna oparta na pomiarze światła widzialnego (LTA). Do próbki badanego osocza bagatopłytkowego dodawany jest w odpowiednim stężeniu określony agonista agregacji PLT (ADP, kwas arachidonowy, kolagen, rystocetyna, epinefryna). Na skutek interakcji z agonistą dochodzi do aktywacji i następczej agregacji płytek krwi. Powstawaniu agregatów płytkowych towarzyszy proporcjonalny wzrost przepuszczalności światła. W pracy przedstawiono zasadę metody LTA wraz z omówieniem podstawowego panelu agonistów agregacji płytek krwi. Ponadto scharakteryzowano mocne strony metody LTA i ograniczenia oraz porównano ją z pozostałymi alternatywnymi metodami diagnostyki PFD.","PeriodicalId":52961,"journal":{"name":"Global Journal of Transfusion Medicine","volume":"95 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135040883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joanna Janus, Katarzyna Chmielewska, Jolanta Antoniewicz-Papis
{"title":"Wybrane zagadnienia dotyczące terapii komórkowych w świetle doniesień prezentowanych na 33. Regionalnym Kongresie International Society of Blood Transfusion (ISBT) w Göteborgu, 17–21 czerwca 2023 roku","authors":"Joanna Janus, Katarzyna Chmielewska, Jolanta Antoniewicz-Papis","doi":"10.5603/jtm.97415","DOIUrl":"https://doi.org/10.5603/jtm.97415","url":null,"abstract":"","PeriodicalId":52961,"journal":{"name":"Global Journal of Transfusion Medicine","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135040888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wiktoria Ryżewska, Michał Witkowski, Tadeusz Robak
Acquired haemophilia A is an autoimmune bleeding disorder treated with immunosuppression and bypassing agents such as recombinant factor VIIa (rFVIIa). The half time of rFVIIa is short, which requires frequent bolus injections in order to maintain hemostasis. Providing a continuous pump infusion instead of bolus injections could not only be more time and cost- -efficient but also safer by maintaining a constant level of the bypassing agent. rFVIIa is administered intravenously usually through a peripheral venous catheter. In patients with prolonged intravenous treatment or difficult-to-access peripheral vasculature, midline long peripheral intravenous catheters are an interesting alternative. They have favourable dwell times and failure rates while maintaining the same risk of infection as other peripherally inserted central catheters. This technique has the potential to reduce the costs as well as risk to the patients. Herein, we report a case of a patient with AHA, who was treated with rFVIIa by an infusion pump and midline catheter.
{"title":"Acquired haemophilia A treated with recombinant factor VIIa by an infusion pump and midline catheter","authors":"Wiktoria Ryżewska, Michał Witkowski, Tadeusz Robak","doi":"10.5603/jtm.2023.0007","DOIUrl":"https://doi.org/10.5603/jtm.2023.0007","url":null,"abstract":"Acquired haemophilia A is an autoimmune bleeding disorder treated with immunosuppression and bypassing agents such as recombinant factor VIIa (rFVIIa). The half time of rFVIIa is short, which requires frequent bolus injections in order to maintain hemostasis. Providing a continuous pump infusion instead of bolus injections could not only be more time and cost- -efficient but also safer by maintaining a constant level of the bypassing agent. rFVIIa is administered intravenously usually through a peripheral venous catheter. In patients with prolonged intravenous treatment or difficult-to-access peripheral vasculature, midline long peripheral intravenous catheters are an interesting alternative. They have favourable dwell times and failure rates while maintaining the same risk of infection as other peripherally inserted central catheters. This technique has the potential to reduce the costs as well as risk to the patients. Herein, we report a case of a patient with AHA, who was treated with rFVIIa by an infusion pump and midline catheter.","PeriodicalId":52961,"journal":{"name":"Global Journal of Transfusion Medicine","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136278817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zespół antyfosfolipidowy (APS) jest ogólnoustrojowym schorzeniem autoimmunologicznym, który charakteryzuje się klinicznym występowaniem epizodów zakrzepowych, a u kobiet także powikłań położniczych, oraz laboratoryjną obecnością we krwi przeciwciał antyfosfolipidowych. Zasadniczym celem pracy jest szczegółowe przedstawienie nowych kryteriów klasyfikacyjnych APS, opracowanych przez American College of Rheumatology (ACR) i Alliance of Associations for Rheumatology (EULAR). Zgodnie z metodologią EULAR zawierają one kryterium wstępne, którego spełnienie jest niezbędne, aby rozpocząć proces klasyfikacji, oraz składają się z 8 domen klinicznych i laboratoryjnych, pozwalających zakwalifikować chorego jako cierpiącego na APS z 99-procentową swoistością.
{"title":"Nowe kryteria klasyfikacyjne zespołu antyfosfolipidowego — 2023","authors":"Jacek Musiał","doi":"10.5603/jtm.97598","DOIUrl":"https://doi.org/10.5603/jtm.97598","url":null,"abstract":"Zespół antyfosfolipidowy (APS) jest ogólnoustrojowym schorzeniem autoimmunologicznym, który charakteryzuje się klinicznym występowaniem epizodów zakrzepowych, a u kobiet także powikłań położniczych, oraz laboratoryjną obecnością we krwi przeciwciał antyfosfolipidowych. Zasadniczym celem pracy jest szczegółowe przedstawienie nowych kryteriów klasyfikacyjnych APS, opracowanych przez American College of Rheumatology (ACR) i Alliance of Associations for Rheumatology (EULAR). Zgodnie z metodologią EULAR zawierają one kryterium wstępne, którego spełnienie jest niezbędne, aby rozpocząć proces klasyfikacji, oraz składają się z 8 domen klinicznych i laboratoryjnych, pozwalających zakwalifikować chorego jako cierpiącego na APS z 99-procentową swoistością.","PeriodicalId":52961,"journal":{"name":"Global Journal of Transfusion Medicine","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135040702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Platelet function disorders (PFD) are a rare and heterogeneous group of hemorrhagic diathesis. Comprehensive diagnostics of impaired platelet function (PLT) — the so called thrombocytopathy — requires the use of special testing. The gold standard for measurement/diagnostics of platelet function disorders is light transmission aggregometry (LTA). A platelet agonist (ADP, arachidonic acid, collagen, ristocetin, epinephrine) is added at an appropriate concentration to the sample of platelet-rich plasma. The interaction with the agonist leads to platelet activation and subsequent platelet aggregation. Aggregate formation is accompanied by a corresponding increase in light transmission. This review presents the principle of the LTA method, and a discussion of the basic panel of platelet aggregation agonists. In addition, the strengths and limitations of the LTA method are characterized and the method is compared with other alternative methods of PFD diagnostics.
{"title":"Light transmission aggregometry in the diagnosis of thrombocytopathy","authors":"Daria Malarczyk, Edyta Odnoczko","doi":"10.5603/jtm.2023.0006","DOIUrl":"https://doi.org/10.5603/jtm.2023.0006","url":null,"abstract":"Platelet function disorders (PFD) are a rare and heterogeneous group of hemorrhagic diathesis. Comprehensive diagnostics of impaired platelet function (PLT) — the so called thrombocytopathy — requires the use of special testing. The gold standard for measurement/diagnostics of platelet function disorders is light transmission aggregometry (LTA). A platelet agonist (ADP, arachidonic acid, collagen, ristocetin, epinephrine) is added at an appropriate concentration to the sample of platelet-rich plasma. The interaction with the agonist leads to platelet activation and subsequent platelet aggregation. Aggregate formation is accompanied by a corresponding increase in light transmission. This review presents the principle of the LTA method, and a discussion of the basic panel of platelet aggregation agonists. In addition, the strengths and limitations of the LTA method are characterized and the method is compared with other alternative methods of PFD diagnostics.","PeriodicalId":52961,"journal":{"name":"Global Journal of Transfusion Medicine","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136278816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：